{"id":"dexamethasone-0-1-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Posterior subcapsular cataract formation"},{"rate":null,"effect":"Local irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Secondary ocular infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell infiltration and cytokine release. In ophthalmic suspension form, it penetrates ocular tissues to provide local anti-inflammatory effects while minimizing systemic exposure. This mechanism makes it effective for treating various inflammatory and allergic eye conditions.","oneSentence":"Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors and inhibiting pro-inflammatory mediator production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:22.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe"},{"name":"Allergic conjunctivitis"},{"name":"Acute inflammatory conditions of the anterior uveal tract"},{"name":"Corneal injury from chemical, radiation, or thermal burns"},{"name":"Post-operative inflammation following ocular surgery"}]},"trialDetails":[{"nctId":"NCT05716945","phase":"PHASE4","title":"The OPTIMISE Study","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-07-29","conditions":"Pseudophakic Bullous Keratopathy, Fuchs' Endothelial Dystrophy, Intraocular Pressure","enrollment":342},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":"Inflammation Eye","enrollment":92},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":"Open-angle Glaucoma","enrollment":53},{"nctId":"NCT00941486","phase":"PHASE2","title":"FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis","status":"TERMINATED","sponsor":"Shire","startDate":"2009-06-30","conditions":"Acute Adenoviral Conjunctivitis","enrollment":30},{"nctId":"NCT01470664","phase":"PHASE2","title":"FST-100 in the Treatment of Acute Adenoviral Conjunctivitis","status":"COMPLETED","sponsor":"Shire","startDate":"2012-12-17","conditions":"Acute Adenoviral Conjunctivitis","enrollment":176},{"nctId":"NCT02998541","phase":"PHASE3","title":"Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo","status":"TERMINATED","sponsor":"Shire","startDate":"2017-03-27","conditions":"Adenoviral Conjunctivitis","enrollment":219},{"nctId":"NCT03004924","phase":"PHASE3","title":"Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo","status":"COMPLETED","sponsor":"Shire","startDate":"2017-03-29","conditions":"Bacterial Conjunctivitis","enrollment":753},{"nctId":"NCT02998554","phase":"PHASE3","title":"Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo","status":"TERMINATED","sponsor":"Shire","startDate":"2017-03-28","conditions":"Adenoviral Conjunctivitis","enrollment":156},{"nctId":"NCT02079649","phase":"PHASE2","title":"Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-04","conditions":"Allergic Conjunctivitis","enrollment":224},{"nctId":"NCT01001091","phase":"PHASE2","title":"AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-12","conditions":"Allergic Conjunctivitis","enrollment":312},{"nctId":"NCT01119287","phase":"PHASE4","title":"Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-03","conditions":"Allergic Conjunctivitis","enrollment":180},{"nctId":"NCT00362895","phase":"PHASE3","title":"A Bioequivalence Study of Tobradex AF","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":"Cataract","enrollment":995},{"nctId":"NCT00447577","phase":"PHASE4","title":"Zylet vs TobraDex in Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-01","conditions":"Blepharokeratoconjunctivitis","enrollment":276},{"nctId":"NCT00532961","phase":"PHASE4","title":"Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-02","conditions":"Inflammation","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexamethasone 0.1% ophthalmic suspension","genericName":"Dexamethasone 0.1% ophthalmic suspension","companyName":"Azienda USL Reggio Emilia - IRCCS","companyId":"azienda-usl-reggio-emilia-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors and inhibiting pro-inflammatory mediator production. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Allergic conjunctivitis, Acute inflammatory conditions of the anterior uveal tract.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}